PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes v...

Descripción completa

Detalles Bibliográficos
Autores principales: Dillon, Kasia M., Bekele, Raie T., Sztupinszki, Zsofia, Hanlon, Timothy, Rafiei, Shahrzad, Szallasi, Zoltan, Choudhury, Atish D., Mouw, Kent W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242979/
https://www.ncbi.nlm.nih.gov/pubmed/35768576
http://dx.doi.org/10.1038/s41698-022-00291-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242979/
https://www.ncbi.nlm.nih.gov/pubmed/35768576
http://dx.doi.org/10.1038/s41698-022-00291-7

Ejemplares similares